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Summary
 
T cell receptors on CD4
 
1
 
 lymphocytes recognize antigen-derived peptides presented by major
histocompatibility complex (MHC) class II molecules. A very limited set of peptides among
those that may potentially bind MHC class II is actually presented to T lymphocytes. We here
examine the role of two receptors mediating antigen internalization by antigen presenting cells,
type IIb2 and type III receptors for IgG (Fc
 
g
 
RIIb2 and Fc
 
g
 
RIII, respectively), in the selection
of peptides for presentation to T lymphocytes. B lymphoma cells expressing recombinant
Fc
 
g
 
RIIb2 or Fc
 
g
 
RIII were used to assess the presentation of several epitopes from two differ-
ent antigens. 4 out of the 11 epitopes tested were efficiently presented after antigen internaliza-
tion through Fc
 
g
 
RIIb2 and Fc
 
g
 
RIII. In contrast, the 7 other epitopes were efficiently pre-
sented only when antigens were internalized through Fc
 
g
 
RIII, but not through Fc
 
g
 
RIIb2.
The capacity to present these latter epitopes was transferred to a tail-less Fc
 
g
 
RIIb2 by addition
of the Fc
 
g
 
RIII-associated 
 
g
 
 chain cytoplasmic tail. Mutation of a single leucine residue at posi-
tion 35 of the 
 
g
 
 chain cytoplasmic tail resulted in the selective loss of presentation of these
epitopes. Therefore, the nature of the receptor that mediates internalization determines the se-
lection of epitopes presented to T lymphocytes within single protein antigens.
 
A
 
ntigen receptors on CD4
 
1
 
 helper T lymphocytes rec-
ognize short peptides presented by class II molecules
of MHC (1, 2). Antigenic peptides are generated by pro-
teolytic degradation in the endocytic pathway, where they
associate with MHC class II molecules. Only a very limited
set of peptides among all the potential peptides is actually
loaded onto MHC class II molecules in APCs (3). The
mechanisms underlying the selection of peptides for MHC
class II–restricted antigen presentation are yet unclear.
However, we know that two independent complex pro-
cesses of intracellular transport towards endosomes are cru-
cial for MHC class II–restricted antigen presentation: the
traffic of MHC class II molecules and the delivery of anti-
gens (4, 5).
MHC class II intracellular transport has been analyzed in
detail. Newly synthesized MHC class II molecules reach
endosomes, either directly from the 
 
trans
 
-golgi network or
after a short appearance at the plasma membrane, in associ-
ation to the invariant (Ii)
 
1
 
 chain (5). Ii is then degraded and
the class II–associated Ii chain peptide (CLIP) is replaced by
an antigenic peptide under the control of HLA-DM (6). It
has recently become clear that an alternative, Ii chain–inde-
pendent pathway for MHC class II transport to endosomes
also exists. Indeed, MHC class II molecules may reach the
endocytic pathway from the cell surface by endocytosis (7),
due to internalization signals present in the cytosolic do-
main of the MHC class II 
 
b
 
 chain (8). Newly synthesized
and recycling MHC class II molecules may present differ-
ent peptides (9). Accordingly, we have previously shown
that different antigen receptors may also selectively target
antigens for presentation by either of these MHC class II
presentation pathways (10).
 
1
 
Abbreviations used in this paper:
 
 Ii, invariant chain; ITAM, immunorecep-
tor tyrosine kinase activation motif; HEL, hen egg lysozome; HRP,
horseradish, peroxidase; PTK, protein tyrosine kinase.
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Influence of Antigen Receptors on the Selection of T Cell Epitopes
 
In contrast, very little is known about the endocytic
transport of antigen receptors. Physiologically, antigens are
delivered to the endocytic pathway by different families of
receptors, which strongly increase the efficiency of MHC
class II–restricted antigen presentation (11). In B lympho-
cytes, surface Ig mediates both cell activation and the up-
take of specific antigens (12), while the expression of a par-
ticular endocytosis-deficient receptor for the Fc portion of
IgG (Fc
 
g
 
RIIb1) prevents efficient presentation of irrelevant
IgG-complexed antigens (13). Interestingly, the epitope
specificity of surface Ig positively and negatively influences
the presentation of various T cell epitopes (14, 15).
In monocytes and dendritic cells, receptors for IgG
(Fc
 
g
 
Rs), in addition to mannose receptors, mediate antigen
internalization and strongly increase the efficiency of pre-
sentation to specific T cells (16). Two different Fc
 
g
 
Rs,
type IIb2 and type III (Fc
 
g
 
RIIb2 and Fc
 
g
 
RIII) are ex-
pressed in dendritic cells. Fc
 
g
 
RIIb2 is a monomeric recep-
tor that, like Fc
 
g
 
RIIb1, mediates the inhibition of cell acti-
vation when cocrosslinked to surface Ig (13). Fc
 
g
 
III is an
heterotrimer consisting of an 
 
a
 
 chain and a dimer of 
 
g
 
chains, which couple the receptor to cytoplasmic effectors
of signal transduction (17).
To individually analyze the function of these two recep-
tors, we expressed them by cDNA transfection into an Fc
 
g
 
R-
negative B cell lymphoma cell line (13, 18, 19). We have
previously shown that the amino acid sequence, called im-
munoreceptor tyrosine kinase activation motif (ITAM),
in the Fc
 
g
 
III-associated 
 
g
 
 chain responsible for cell activa-
tion is also involved in receptor internalization (18, 19). In
addition, mutation of either of the two tyrosine residues
in the ITAM of the 
 
g
 
 chain inhibits both cell activation and
ligand internalization (19). Thus, in contrast to Fc
 
g
 
RIIb2,
which contains no ITAM, is not tyrosine phosphorylated,
and does not induce cell activation, Fc
 
g
 
RIII associates with
and activates cytosolic tyrosine kinases after engagement by
its ligand (18). In addition to this functional diversity of the
two receptors, their expression is also selectively regulated,
since TNF-
 
a
 
 and IFN-
 
g
 
 increase the expression of Fc
 
g
 
RIII
and inhibit that of Fc
 
g
 
RIIb2 in monocytes (20).
The diversity in the signals required of Fc
 
g
 
RIIb2 and
Fc
 
g
 
RIII internalization, as well as the differential regula-
tion of their expression in APCs, suggest that the two re-
ceptors may have different antigen-presenting functions. We
here examine the ability of Fc
 
g
 
RIIb2 and Fc
 
g
 
RIII to in-
duce the presentation of various T cell epitopes from two
different antigens, CI 
 
l
 
 repressor and hen egg lysozyme
(HEL). 
Internalization of antigen–antibody complexes through
Fc
 
g
 
RIII induced the efficient presentation of all the T cell
epitopes tested, whereas Fc
 
g
 
RIIb2 only induced the pre-
sentation of a few. Point mutation of leucine 35 to alanine
(L35A) in the cytoplasmic tail of Fc
 
g
 
RIII 
 
g
 
 chain blocked
signal transduction without affecting the internalization of
immune complexes. This mutation also blocked the pre-
sentation of the epitopes that were only presented after inter-
nalization by Fc
 
g
 
RIII. In contrast, the presentation of all
 
the epitopes that were efficiently generated after internal-
ization by Fc
 
g
 
RIIb2 was not affected. Thus, the nature of
the receptor that mediates antigen internalization influences
the selection of the epitopes presented to T lymphocytes.
 
Materials and Methods
 
B Lymphoma Cell Lines.
 
The B lymphoma IIA1.6 is a type II
Fc
 
g
 
R–defective variant of A20 B lymphoma cells (21) that also
lacks expression 
 
a
 
 and 
 
g
 
 chains of type III Fc
 
g
 
R (18). This cell
line was cultured in RPMI 1640 containing 10% FCS, 10 mM
glutamine, 100 U/ml penicillin, 100 
 
m
 
g/ml streptomycin, 50
 
m
 
M 2-mE, and 5 mM sodium pyruvate (GIBCO, Paisley, UK).
Fc
 
g
 
RII–ic
 
g
 
 chimeras were constructed by adding the sequences
encoding the cytoplasmic domain of the 
 
g
 
 chain to cDNA en-
coding the extracellular and transmembrane domains of mouse
Fc
 
g
 
II (18). The cDNAs were stably expressed by transfection in
the mouse B cell line IIA1.6 as previously described (18). IIAI.6
cells expressing tail minus Fc
 
g
 
RII have been previously described
(13). Fc
 
g
 
RII–ic
 
g
 
L35 chimeras were constructed by using PCR
with the two complementary oligonucleoides GAGACATAT-
GAGACT
 
GCG
 
AAGCATGAAAAACCA and TGGTTTTT-
CATGCTT
 
CGC
 
AGTCTCATATGTCTC. They introduced an
alanine residue in place of the leucine at position 35 of the cyto-
plasmic domain of the 
 
g
 
 chain in the Fc
 
g
 
RII–ic
 
g
 
 chimeras. The
resulting construction was inserted in expression vectors and se-
quenced, and cDNA were stably expressed by transfection in the
mouse B cell line IIA1.6 as previously described (18). Cell surface
expression of Fc
 
g
 
Rs was measured with the rat anti–mouse Fc-
 
g
 
RII and III mAb 2.4G2 and revealed by FITC-coupled mouse
 
Table 1.
 
Presentation of Different T Cell Epitopes after Antigen 
Internalization through Fc
 
g
 
RIIb2 and Fc
 
g
 
RIII
 
T cell
hybridoma Specificity Fc
 
g
 
RIIb2
 
§
 
Fc
 
g
 
RIII
 
§
 
L35A
 
§
 
24.4 CI/IA
 
d
 
 12-26
 
1
 
*
 
11
 
26.1 CI/IE
 
d
 
 12-26
 
2
 
‡
 
12
 
A128 CI/IA
 
d
 
 46-64
 
11 1
 
4G.2 CI/IA
 
d
 
 80-102
 
21 2
 
9C12.7 CI/IA
 
d
 
 12-26
 
11
 
ND
B9.1 HEL/IE
 
d
 
 108-116
 
21 2
 
CAB43 HEL/IA
 
d
 
 11-25
 
21 2
 
Ad71 HEL/IA
 
d
 
 71-85
 
21
 
ND
930B2 HEL/IA
 
d
 
 11-25
 
11
 
ND
G28C9 HEL/IEd 106-116 21 ND
16F2QCOY HEL/IEd 2-16 21 ND
*1 stands for an increase (of at least 30-fold) in the efficiency of antigen
presentation of immune complexes as compared to free antigen.
‡2 denotes a similar efficiency of antigen presentation of free antigen
and immune complexes.
§The data reported in this table summarize the results of five indepen-
dent experiments for the C1-specific hybridomas and three experiments
for the HEL-specific hybridomas.507 Amigorena et al.
anti–rat antibodies. The samples were analyzed with a FACScanÒ
flow cytometer (Becton Dickinson, San Jose, CA).
T Cell Hybridomas. Culturing of the T cell hybridomas and
antigen presentation assays were performed in RPMI 1640 con-
taining 10% FCS, 10 mM glutamine, 100 U/ml penicillin, 100
mg/ml streptomycin, and 5 3 1025 M 2-ME. The specificity of
all the CD41 T cell hybridoma is shown in Table 1. The CI l re-
pressor–specific hybridomas 24.4, A128, 26.1, 9C12, and 4G2
were previously characterized (22–24). The anti-HEL T cell hy-
bridomas B9.1 and CAB43 have been previously described (25),
and Ad71, 930B2, G28C9, and 16F2QCOY (3) were obtained
from Dr. E. Sercarz (University of California, Los Angeles, CA).
Assays for Antigen Presentation. Antigen presentation was as-
sessed by culturing transfected IIA1.6 cells together with specific
T cell hybridomas for 18–20 h in the presence of various concen-
trations of l repressor or HEL, complexed or not with two
mAbs, 22D and 51F, that recognize distinct epitopes on the l re-
pressor (13), or F10.6.14 and F9.13.7, which recognize distinct
epitopes on HEL (26). The complexes were preformed by incu-
bating different concentrations of purified l repressor or HEL
(from 30,000 ng to 0.5 ng) with 15 mg/ml of each of two differ-
ent mAbs (51F and 22D or F10.6.14 and F9.13.7) at 378C for 15
min. The release of IL-2 by the T-cell hybridoma was deter-
mined using a CTL.L2 proliferation assay (13). Each point repre-
sents the average of duplicate samples, which varied by ,5%.
Kinetics analysis was performed as previously described (10). In
brief, a dose of antigen (3 mg/ml) was used for which presenta-
tion was strictly dependent on immune complex formation with
the mAbs. Immune complexes were preformed at 378C by mix-
ing the purified l repressor with 51F and 22D mAbs, to make a
103 mix in the culture medium. 30 ml of preformed immune
complexes were added to 270 ml of APCs adjusted at 2 3 106
cells/ml and incubated at 378C for different times. The cells were
then washed twice with PBS, fixed with 0.05% glutaraldehyde
for 20 min on ice, and washed again twice. Fixed cells, in dupli-
cate samples of 100 ml, were added to 50 ml of T cell hybridomas
and adjusted to 2 3 106 cells/ml. After 24 h, IL-2 production was
tested as above. When indicated, APCs were preincubated for 3 h
at 378C with 10 mg/ml cycloheximide diluted from a stock solu-
tion at 10 mg/ml in water. In this case, cycloheximide was also
present during the incubation times with preformed immune
complexes before fixation with glutaraldehyde.
Ovalbumin immune complexes were made by mixing ovalbu-
min (15 mg/ml; Sigma Chemical Co., St. Louis, MO) and the IgG
fraction of a rabbit antiovalbumin antiserum (50 mg/ml; Sigma
Chemical Co.). The binding of these immune complexes to FcRs
was controlled by immunofluorescence and FACScanÒ analysis.
For costimulation experiments, APCs were incubated with or
without ovalbumin immune complexes for 18 h and then fixed as
described above. Fixed cells, in duplicate samples of 100 ml, were
added to 50 ml of T cell hybridomas 24.4 and 26.1 (adjusted to 2
3 106 cells/ml) and various concentrations of CI l repressor 12–
26 peptides. In another set of experiments, APCs were incubated
either with l repressor (30 mg/ml) and preformed ovalbumin im-
mune complexes to stimulate FcR, or with preformed l repressor
immune complexes (as described above) and F(ab9)2 fragments of
specific goat anti–mouse IgG2a antibodies (15 mg/ml; Southern
Biotechnology Associated, Birmingham, AL), which do not
cross-react with IgG1 anti-l repressor mAbs 51F and 22D, and
which specifically stimulate endogenous membrane IgG2a on
IIA1.6 cells. After 18 h, the cells were fixed and incubated with
CI l repressor–specific T cell hybridomas 24.4 and 26.1. T cell
stimulation was assayed using a CTL.L2 proliferation assay.
Assays for Cell Activation. Cell activation through Fc recep-
tors or endogenous membrane immunoglobulins was determined
as previously described (19). In brief, triplicates of each B lym-
phoma cell (105 cells/well in 100 ml) were stimulated either
through Fc receptors using preformed ovalbumin immune com-
plexes, made as described above, or through endogenous mem-
brane immunoglobulins using F(ab9)2 fragments of the IgG frac-
tion of a rabbit anti–mouse IgG antisera (15 mg/ml). After 18 h,
the supernatants were harvested and their content in I1-2 was
measured using a CTL.L2 proliferation assay.
Immune Complex Internalization. The internalization of im-
mune complexes was assayed as previously described (19). In
brief, the cells were washed once in internalization buffer (RPMI,
5% FCS, 10 mM glutamine, 5 mM sodium pyruvate, 50 mM
2-ME, and 20 mM Hepes, pH 7.4) and incubated with horserad-
ish peroxidase (HRP) anti-HRP immune complexes for 2 h at
08C (107 cells/ml). Immune complexes were prepared as a 103
solution in internalization buffer (HRP 50 mg/ml and a poly-
clonal rabbit anti-HRP antibody at 400 mg/ml) for 30 min at
378C. After fixation of HRP immune complexes, the cells were
washed three times in internalization buffer and incubated at
378C for various times (2 3 106 cells/ml). Internalization was
stopped by adding cold internalization buffer and the cells were
washed once in PBS. Duplicates of each time point were either
Figure 1. Selective presentation of a cryptic epitope after antigen–IgG
complexes internalization through FcgRIII. IIA1.6 cells expressing either
FcgRIIb2 or FcgRIII a and g chains were cultured in the presence of in-
creasing concentrations of CI l repressor (fluid phase uptake, open sym-
bols) or CI l repressor–IgG complexes (FcR-mediated endocytosis, filled
symbols). T cell hybridomas specific for a dominant epitope (IA/12–26) or
a cryptic epitope (IE/12–26) from the CI l repressor were also included
in the cultures. The secretion of IL-2 by the T cell hybrids was measured
after an overnight incubation. (a) Internalization through both FcRs re-
sulted in the efficient presentation of the dominant IAd-restricted epitope,
whereas only FcgRIII-expressing cells presented the IEd-restricted
epitope. (b) Both transfected cell lines presented the 12–26 peptide on IAd
or IEd with identical efficiencies. The data presented are representative of
results obtained in three independent experiments.508 Influence of Antigen Receptors on the Selection of T Cell Epitopes
left in PBS at 48C to measure cell surface HRP-ICs or incubated in
Triton X-100 (0.1%) for 59 at room temperature to measure the
total amount of HRP-ICs. The HRP was revealed by adding
substrate buffer (0.5 mg/ml OPD [Sigma Chemical Co.] and
0.12% H2O2 in 0.05 M phospho-citrate buffer, pH 5.0) at 48C.
The reaction was stopped with 6 N HCl and the change in color
was determined spectrophotometrically at 492 nm.
Results
Selective Presentation of a T Cell Epitope after Antigen Inter-
nalization by FcgRIII. We have shown previously that inter-
nalization of antigen–IgG complexes by FcgRIIb2 and III
in IIA1.6 cells (an FcgR-negative B lymphoma cell line
derived from A20 cells) induces presentation of the domi-
nant epitope of the CI l repressor (12–26 peptide on IAd)
at antigen concentrations 102–104-fold lower than fluid
phase uptake (13, 19). This increase in the efficiency of an-
tigen presentation is, at least in part, due to increased anti-
gen uptake by the APCs since endocytosis-incompetent re-
ceptors for IgG (13, 19) were deficient for both internalization
of immune complexes and efficient presentation at low an-
tigen concentrations. Although these results underline the
importance of internalization in antigen presentation, they
do not address the possibility that postinternalization intra-
cellular targeting of antigen–receptor complexes is also im-
portant for the generation of certain epitopes. If this was
the case, we would then expect that internalization through
particular antigen receptors results in the presentation of
different epitopes to specific T lymphocytes.
To test this possibility, we assessed the ability of cells ex-
pressing either FcgRIIb2 or FcgRIII (cells coexpressing
the a and g chains, which we have previously shown to
present the 12–26/IAd epitope at very low antigen-IgG
concentrations) to present another epitope, defined by the
same 12–26 in association with I-Ed. This epitope is not
presented after fluid phase antigen uptake, or in vivo after
immunization with intact antigen (it is therefore a cryptic
epitope), but it elicited an immune response when the
mice were injected directly with the peptide (22).
The cell lines expressing either FcgRIIb2 or FcgRIII
were incubated with increasing concentrations of CI l re-
pressor, free or complexed to two different anti-l repressor
mAbs, as previously described (13). Complexing antigen to
IgG allowed receptor-mediated antigen uptake through
FcgRs. T cell hybridomas specific for either IAd- or the
IEd-restricted epitopes were also included in the cultures.
Antigen presentation was assessed by measuring IL-2 secre-
tion by the T cell hybridomas.
As shown in Fig. 1 A, the IEd restricted epitope was not
presented after fluid phase uptake (right), whereas the IAd-
restricted epitope was presented at high antigen concentra-
tions (left). Confirming our previous results, FcgRIIb2 in-
creased the efficiency of presentation of the IAd restricted
epitope by 3–4 logs when the C1 l repressor was complexed
to IgGs (T cell activation was still observed at 30 ng/ml). Sim-
ilarly, FcgRIII-mediated internalization induced presenta-
tion of this epitope at concentrations 30–100-fold lower
than fluid phase uptake. Therefore, both type II and III
IgG receptors increased the efficiency of presentation of
this dominant IAd-restricted epitope.
However, FcgRIII was less efficient than FcgRIIb2
(Fig. 1 A, compare lower and upper left). This difference
was due to the different levels of expression of the two re-
ceptors, since FcgRII and FcgRIII were expressed at 1.6 3
105 molecules/cell and 2.8 3 104 molecules/cell, respec-
tively (reference 19 and data not shown). When cells ex-
pressing 2–3 3 104 FcgIIb2 per cell were used, the effi-
ciency of presentation was similar to that obtained with
FcgRIII expressing cells (data not shown).
In contrast to this IAd-restricted epitope, the IEd epitope
was not presented after FcgRIIb2-mediated internalization
of immune complexes (Fig. 1 A, lower right). In contrast, ef-
ficient presentation of 12–26 on IEd was observed with Fc-
gRIII-expressing cells after internalization of immune
complexes (upper right). This selectivity of presentation of
the IEd-restricted epitope was not due to a difference be-
tween the FcgRIIb2 and FcgRIII cell lines in the levels of
Figure 2. Presentation of the IEd-restricted cryptic epitope requires the
cytoplasmic tail of the FcgRIII-associated g chain. (a) IIA1.6 cells ex-
pressing either a tail-less FcgRII (FcgRII/ic2) or a chimera composed of
the extracellular and transmembrane domains of FcgRII and the cytoplas-
mic tail of the FcgRIII-associated g chain (FcgRII–icg) were assayed for
presentation of free (black symbols) and IgG-complexed (white symbols) CI
l repressor. The chimera presented both the dominant IAd-restricted
epitope and the cryptic IEd-restricted epitope with high efficiency when
the antigen was complexed to IgG (i.e., after receptor-mediated endocy-
tosis). The tail-less FcgRII, in contrast, presented the dominant epitope
inefficiently and was completely unable to present the cryptic epitope. (b)
Both transfected cell lines presented the 12–26 peptide with similar effi-
ciencies, indicating that the levels of IAd and IEd expression in both cell
lines were the same. The data presented are representative of results ob-
tained in five independent experiments for a and two experiments for b.509 Amigorena et al.
surface expression of either MHC class II or other costimula-
tory molecules, because the 12–26 peptide was presented
with similar efficiencies to the two T cell hybridomas by
the two transfected cell lines (Fig. 1 B). Since engagement
of FcgIII by immune complexes may, under certain cir-
cumstances (see below), induce IL-2 secretion by A20 and
IIA1.6 cells (18, 27), we verified that the CI l repressor
immune complexes did not induce any IL-2 secretion in
the absence of T cell hybridomas (data not shown).
Therefore, only FcgRIII-mediated internalization in-
duced presentation of the 12–26 peptide on IEd. FcgRIIb2,
which induced very efficient presentation of the same pep-
tide on IAd, was totally inefficient for the presentation of
the IEd-restricted epitope. Therefore, receptor-mediated
antigen internalization is not sufficient for presentation of
all T cell epitopes; the nature of the receptor mediating an-
tigen uptake influences the selection of epitopes presented
to T lymphocytes.
Presentation of the IEd-restricted Epitope Requires the FcgRIII-
associated g Chain. We have shown previously that both
the internalization and the increased efficiency of presenta-
tion of the IAd/12–26 dominant epitope in the CI l re-
pressor were dependent on the FcgRIII-associated g chains
(19). Thus, FcgRIII with a cytoplasmic domain–deleted g
chain did not internalize ligand or promote antigen presen-
tation at low concentrations. In addition, when the cyto-
plasmic domain of the g chain was fused to the extracellular
and transmembrane domains of FcgRIIb2, cell activation,
immune complex internalization, and efficient antigen pre-
sentation were observed (19). Therefore, we next sought to
assess if the presentation of 12–26 on IEd was also depen-
dent on the FcgRIII-associated g chain.
As expected, the tail-less FcgRIIb2, which was not in-
ternalized, did not allow the efficient presentation of the
two epitopes (Fig. 2 A, lower panels). In contrast, when the
cytoplasmic tail of the g chain was fused to this tail-less re-
ceptor to form an FcgRII/icg chimera, efficient presenta-
tion of both IAd/12–26 and IEd/12–26 was observed after
immune complex internalization (Fig. 2 A, upper panels).
The cell lines expressing the tail-less FcgRII and the Fc-
gRII/icg chimeras presented the 12–26 peptide with simi-
lar efficiencies (Fig. 1 B). Therefore, the cytoplasmic do-
main of the g chain bears all the information required for
the presentation of the IEd epitope.
Presentation of Both IAd- and IEd-restricted Epitopes Requires
Newly Synthesized MHC Class II Molecules. Two differ-
ent pathways of antigen presentation may result in the
loading of antigenic peptides on MHC class II molecules:
the conventional pathway requires newly synthesized and
the so-called alternative pathway requires recycling MHC
class II. Presentation through the conventional and alterna-
tive pathways differ by their kinetics and their sensitivity to
protein synthesis inhibitors (as well as by their dependence
on H2-M, the Ii chain, and the cytoplasmic tail of MHC
class II molecules; references 8, 28). It has recently been
shown, that these two pathways may control the presenta-
tion of different epitopes from a single antigen (9). We
have also previously shown that internalization through
different receptors may trigger the presentation the same
epitope by either antigen presentation pathways (10).
Therefore, it was possible that FcgRIIb2 and FcgRIII were
also targeting antigens for presentation by different path-
ways and that the IEd epitope could only be generated in
one of these pathways.
We tested this possibility by assessing the effect of the
protein synthesis inhibitor cycloheximide on the kinetics of
presentation of the IAd and IEd epitopes. FcgRIIb2- or Fc-
gRIII-expressing cells were preincubated in cycloheximide
for 3 h before addition of CI l repressor immune com-
plexes. After incubation of the cells at 378C for various pe-
riods of time, the cells were fixed and T cell hybrids spe-
cific for the IAd/12–26 or IEd/12–26 epitopes were added.
After an additional 18 h incubation, the amounts of IL-2
produced by the T cell hybrids were measured in the su-
pernatants.
As shown in Fig. 3, presentation of the IAd epitope in
FcgRII- and FcgRIII-expressing cells, as well as presenta-
tion of the IEd epitope by FcgRIII-expressing cells, all ex-
hibited slow kinetics and were blocked by cycloheximide.
These results indicate that both receptors induced antigen
presentation through the conventional pathway, which re-
quires newly synthesized MHC class II molecules. The dif-
ference in the presentation of the IEd epitope is therefore
not due to the targeting of antigen to different antigen pre-
sentation pathways by the two receptors.
Cell Activation Is Not Sufficient for the Presentation of the Cryptic
Epitope. Engagement of FcgRIII, but not of FcgRIIb2,
induces the activation of multiple tyrosine kinases, a rise of
Figure 3. Presentation of the dominant and cryptic epitopes are
blocked by cycloheximide. IIA1.6 cells expressing either FcgRII–icg chi-
meras (top) or FcgRIIb2 receptors (bottom) were incubated with CI l re-
pressor–IgG complexes for various time periods with (1Cx) or without
(2Cx) cycloheximide. The cells were then fixed with gluteraldehyde be-
fore incubation with the T cell hybridomas for 24 h. The presentation of
both the dominant and the cryptic epitopes by FcgRIII, as well as presen-
tation of the dominant epitope by FcgRIIb2, were all blocked in the
presence of cycloheximide. Therefore, both the dominant and cryptic
epitopes are presented by newly synthesized MHC class II molecules.
(Similar results were obtained in three independent experiments).510 Influence of Antigen Receptors on the Selection of T Cell Epitopes
cytosolic Ca21 concentrations and, subsequently, the acti-
vation of the transcription of various genes (18). Therefore,
the selective presentation of the cryptic epitope by cells ex-
pressing FcgRIII could be either a direct consequence of a
different intracellular targeting of antigen or an indirect ef-
fect of overall cell activation. We next attempted to test the
latter possibility in two different ways.
First, we tested whether cell activation by FcgRII/icg
chimera induced a change in surface expression of a puta-
tive costimulatory molecule required only for the efficient
activation of some of the epitope-specific T cell hybrids.
The FcgRIIb2- and FcgRII/icg-expressing cells were in-
cubated overnight with or without irrelevant immune
complexes (ovalbumin (OVA)-anti-OVA), in order to in-
duce cell activation (we verified that these immune com-
plexes induced efficient cell activation using a phosphoty-
rosine blot assay and IL-2 secretion, data not shown). The
cells were then fixed and reincubated with increasing doses
of 12–26 peptide and either the IAd or the IEd 12–26
epitope-specific T cell hybrids.
As shown in Fig. 4 A, the peptide was presented to both
T cell hybridomas with similar efficiencies by the unstimu-
lated and the stimulated cells. Therefore, cell activation
through the g chain did not induce any modification in the
efficiency of presentation of the 12–26 peptide to the IAd
and the IEd specific T cell hybrids. The effect of antigen in-
ternalization through FcgRIII is therefore related to the in-
tracellular processing of antigen.
Second, we tested the effect of cell activation on intra-
Figure 4. Cell activation per se does not induce presentation of the
IEd-restricted epitope. (a) FcgRIIb2- and FcgRII–ic-g chimera–express-
ing cells were incubated for 24 h with OVA–anti-OVA immune com-
plexes. The cells were then incubated with increasing concentrations of
12–26 CI l repressor peptide and the T cell hybridomas specific for the
dominant (IAd 12–26) or cryptic (IEd 12–26) epitopes. The secretion of
IL-2 in the cell culture supernatants was measured. Activation of FcgRII–
icg chimera–expressing cells with IC did not modify the efficiency of pre-
sentation of the 12–26 peptide. Similar results were obtained in three in-
dependent experiments. (b) Cell activation through FcgRII–icg chimeras
does not induce the presentation of the cryptic epitope after antigen inter-
nalization by fluid phase uptake. FcgRII–icg–expressing cells were incu-
bated overnight in the presence of 30 mg/ml CI l repressor, with or
without irrelevant OVA–anti-OVA immune complexes, in order to en-
gage FcgRII–icg chimeric receptors. The cells were then fixed and rein-
cubated overnight with T cell hybridomas specific for the dominant or
the cryptic epitopes. Engagement of FcgRII–icg chimeric receptors did
not induce the presentation of the IEd-restricted cryptic epitope. (c) Cell
activation through surface IgG does not induce the presentation of the CI
l repressor cryptic epitope after immune complexes internalization
through FcgRIIb2. Cells expressing FcgRIIb2 were incubated in the
continuous presence of CI l repressor immune complexes in the absence
or presence of specific goat anti–mouse IgG2a F(ab)92 fragments, in order
to induce cell activation through endogenous surface IgG2a. Cell activa-
tion through sIgG2a did not induce presentation of the cryptic epitope by
FcgRII2b-expressing cells. Error bars in b and c indicate the mean varia-
tion of T cell stimulation in two distinct experiments.
Figure 5. FcgRII–icgL35 receptors have lost the ability to induce cell
activation but are still efficiently internalized. (a) The secretion of IL-2 by
the IIA1.6 cells was measured after engagement of the transfected
FcgRII–icg or FcgRII–icgL35 chimeras or FcgRIIb2 by OVA–anti-
OVA immune complexes. As we have previously shown, FcgRII–icg but
not FcgRIIb2 induce the secretion of IL-2 after binding to immune com-
plexes. The L35 mutation inhibits the induction of IL-2. (b) Internaliza-
tion of the HRP–anti-HRP immune complexes was measured as de-
scribed in Materials and Methods. The three transfected cell lines
internalized immune complexes with similar kinetics and efficiencies.
Data are representative of two independent experiments.511 Amigorena et al.
cellular antigen processing. FcgRII/icg expressing cells
were incubated with soluble CI l repressor in the presence
of irrelevant immune complexes (as in Fig. 4 A) in order to
engage the corresponding receptors, and induce cell activa-
tion. The cells were then fixed and reincubated with either
the IAd or the IEd 12–26 specific T hybridomas. As shown
in Fig. 4 B, activation through FcgRII/icg did not induce
the presentation of the cryptic epitope after fluid phase an-
tigen uptake.
However, it was still possible that both cell activation
and efficient receptor-mediated antigen uptake were re-
quired together for the presentation of the IEd restricted
epitope. To test this possibility, the FcgRIIb2 expressing
cells were simultaneously incubated with l repressor–con-
taining immune complexes (to allow efficient antigen up-
take) and specific anti–mouse IgG2a goat antibodies (to in-
duce cell activation through surface immunoglobulin). The
cells were then fixed and reincubated with the two T cell
hybrids. As shown in Fig. 4 C, cell activation through sIgG
did not induce FcgRIIb2 expressing cells to present the
cryptic epitope. Therefore, overall cell activation is not suf-
ficient to allow presentation of the IEd-restricted epitope
after FcgRIIb2-mediated antigen internalization.
Mutation of Leucine 35 to Alanine in the Cytoplasmic Tail of
FcgRIII-associated g Chain Inhibits Cell Activation, but not In-
ternalization of Immune Complexes. We concluded from
the previous series of experiments that the presentation of
the IEd-restricted epitope was not an exclusive conse-
quence of overall cell activation, but rather resulted from
the selective intracellular targeting of antigen by FcgRIII.
However, the intracellular traffic of membrane receptors
may also be related to their signal transduction capabilities.
In the case of tyrosine kinase receptors, like epidermal
growth factor receptor, the kinase activity is involved in in-
ternalization (29) and endosomal trafficking (30). By anal-
ogy to PTK receptors, we reasoned that the ability of Fc-
gRIII (or FcgRII/icg) to activate PTKs after cross-linking
(17) might influence its intracellular traffic and thereby al-
low the generation of the IEd-restricted epitope.
We attempted to address this possibility by searching for
mutations that differentially affected internalization and cell
activation by the g chain. An alanine scan of the region of
the ITAM (Amigorena, S., and C. Bonnerot, unpublished
results) was performed by sequentially introducing single
point mutations in the cytoplasmic tail of FcgRII/icg. The
corresponding cDNAs were expressed stably in the IIA1.6
B lymphoma cells and the resulting transfectants were
tested for their ability to induce cell activation and ligand
internalization after receptor cross-linking by anti-FcgR
mAbs (Amigorena, S., and C. Bonnerot, unpublished re-
sults). Thus, we found that mutation of leucine in position
35 to alanine (FcgRII/icgL35A) completely abolished cell
activation without affecting receptor internalization.
As shown in Fig. 5 A, FcgRII–icgL35A chimera–express-
Figure 6. Selective effect of
mutation of leucine 35 to alanine
on the presentation of different
epitopes. (a) The presentation of
the dominant and cryptic
epitopes of CI l repressor were
measured on IIA1.6 cells ex-
pressing either FcgRII–icg or
FcgRII–icgL35 receptors as de-
scribed in Fig. 1. Mutation of
leucine 35 to alanine did not sig-
nificantly affect the presentation
of the IAd-restricted epitope. In
contrast, it completely inhibits
presentation of the IEd-restricted
epitope. (b) The two transfected
cell lines present the 12–26 pep-
tide with the same efficiency to
the T cell hybridomas specific
for both epitopes. The data pre-
sented are representative of re-
sults obtained in three indepen-
dent experiments.512 Influence of Antigen Receptors on the Selection of T Cell Epitopes
ing cells have lost the ability to secrete IL-2 after engage-
ment of the receptor by immune complexes, whereas se-
cretion of IL-2 was normal after engagement of surface IgG
in the same cells. In contrast, internalization of immune
complexes was not affected by the mutation (Fig. 5 B).
Therefore, leucine 35 in the g chain cytoplasmic domain is
required for cell activation but dispensable for receptor in-
ternalization.
Internalization through FcgRIII Induces the L35-dependent
Presentation of Multiple Epitopes that were Not Presented after
Internalization through FcgRII. Since FcgRII–icgL35A
was incapable of stimulating IL-2 production or inducing
activation of PTKs (Amigorena, S., and C. Bonnerot, un-
published results) but was normally internalized, we next
tested its ability to induce the presentation of the IAd- and
IEd-restricted 12–26 peptide. As shown in Fig. 6 A, Fc-
gRII–icgL35A–expressing cells presented soluble CI l re-
pressor IAd 12–26 epitope with the same efficiency as Fc-
gRIII-expressing cells. When the cells were incubated with
antigen–IgG complexes, both FcgRIII–icg– and FcgRII–
icgL35A–expressing cells presented the IAd epitope with
high efficiency. In contrast, only FcgRII–icg–expressing cells
presented the IEd 12–26 epitope, whereas absolutely no pre-
sentation of this epitope was observed after immune com-
plexes internalization by FcgRII–icgL35A–expressing cells
(Fig. 6 A, lower panels). The efficiencies of presentation of
the 12–26 peptide to the IAd and IEd-specific T cell hybri-
domas were similar for the FcgRII–icg– and the FcgRII–
icgL35A–expressing cells (Fig. 6 B). The mutation of leu-
cine 35 therefore affected the presentation of the IEd 12–26
epitope much more drastically than the presentation of the
same peptide with IAd.
The two epitopes described this far concern the same or
overlapping peptides (included in the 12–26 region) associ-
ated to either IAd or IEd. We next tested whether the same
effect was found using two other IAd restricted epitopes,
IAd 46–64 and IAd 80–102. As shown in Fig. 7 (upper right),
the 46–64 epitope was efficiently presented after internal-
ization by both FcgRIIb2 and FcgRII–icg. In contrast, the
80–102 peptide was only presented after internalization by
the FcgRII–icg. As in the case of the IEd 12–26 epitope,
the IAd 80–102 epitope was not at all presented after inter-
nalization by FcgRIIb2. In addition, as in the case of the
IEd 12–26 and IAd 12–26, the presentation of the IAd 80–
102, but not of IAd 46–64 epitope, was blocked by the
L35A mutation.
Is the difference in the repertoire of epitopes presented
after FcgRIII or FcgRII–icg antigen internalization lim-
ited to CI l repressor? To answer this question, we tested a
panel of six T cell hybridomas specific for various epitopes
of HEL. The efficiency of presentation of IgG-complexed
HEL to the different T cell hybrids was compared for the
FcgRIIb2– and the FcgRII–icg–expressing cells. As shown
in Fig. 7 (lower panels), the IAd 11–25 and IEd 108–116
epitopes were efficently presented only after internalization
by FcgRII–icg–expressing cells. As in the case of the CI l
repressor IAd 12–26 and IAd 46–64 epitopes, the L35A mu-
tation inhibited the efficient presentation of these two
epitopes.
As summarized in Table 1, internalization by FcgRII–icg
chimeras allowed the efficient presentation of all epitopes
tested, whereas FcgRIIb2 only presented a subset of these
epitopes. For all the other epitopes tested, FcgRIIb2 either
allowed no presentation or induced presentation at the
same high antigen concentrations as those which also in-
duced presentation after fluid phase uptake. As a general
rule, the epitopes which were efficiently presented after in-
ternalization by either FcgRIII or FcgRIIb2 were also effi-
ciently presented by the L35 mutant receptors. In contrast,
in the case of the epitopes that were presented after FcgRIII
and FcgRII–icg, but not presented after internalization by
FcgRIIb2, the L35 mutation inhibited presentation. In all
cases, the L35 mutant receptors behaved like the FcgRIIb2
in terms of epitope presentation.
Discussion
The mechanisms of selection of T cell epitopes within
complex protein antigens are poorly understood. Yet this
choice is critical, on one the hand for shaping the T cell
repertoire during thymic positive and negative selection,
and, on the other hand, for the development of efficient
immune responses. Our results show that the T cell
epitopes that we have analyzed may be classified into two
discrete categories. The first category consists of the
epitopes that were efficiently presented after internalization
by either FcgRII or FcgRIII (which in most cases were
also presented, although less efficiently after fluide phase
uptake), and the second, of the epitopes that were only
presented after internalization by FcgRIII, or the FcgRII–
Figure 7. Mutation of leucine 35 inhibits presentation of the FcgRIII-
restrained epitopes, but does not affect presentation of the epitopes also
presented after internalization by FcgRII. IIA1.6 cells expressing
FcgRIIb2, FcgRII–icg, or FcgRII–icgL35 were incubated with increas-
ing concentrations of CI l repressor immune complexes or HEL immune
complexes. The presentation of two epitopes of the CI l repressor and
two epitopes of HEL were measured with the corresponding T cell hy-
bridomas. For these four epitopes, FcgRII–icgL35 receptors behave like
FcgRIIb2 and not like FcgRII–icg chimeras. The same results were ob-
tained in three independent experiments.513 Amigorena et al.
icg chimeras (at least two of these epitopes were cryptic, i.e.,
not presented after immunization of mice with intact antigen).
Why, then, did FcgRIII and FcgRIIb2/g-chain chime-
ras induce the presentation of epitopes that were not pre-
sented after internalization via FcgRIIb2 or fluid phase up-
take? The selectivity in the presentation of different epitopes
between receptors is certainly not due to quantitative dif-
ferences in the uptake of antigen by the presenting cells,
because (a) both FcgRIII and the FcgRII–chain chimeras
were expressed at lower levels than FcgRIIb2; (b) all recep-
tors mediated the internalization of immune complexes
with similar kinetics and efficiencies (Fig. 5 B); and (c)
FcgRIIb2 increased the efficiency of presentation of several
epitopes to the same extent or even to greater extents than
FcgRIII and the FcgRII–icg chimera (Figs. 1 and 2).
Therefore, the selectivity in epitope presentation must re-
side in a qualitative difference between the two receptors.
One of the qualitative differences between type II and III
FcgRs is in the induction of cell activation. The g chains
have been shown to mediate activation through FcgRIII, due
to a conserved ITAM, present in its cytoplasmic tail. In
contrast, FcgRIIb2 bears no ITAM and does not induce
cell activation. Upon activation through FcgRIII, IIA1.6
cells produced a cytokine that supports the growth of the
CTLL.2 IL-2–dependent cell line (18). We checked very
carefully that the IL2 production measured by the CTLL.2
cells in our antigen presentation experiments was due to
the T cell hybrids and not to the presenting cells. If the
presenting cells were incubated with CI l repressor or
HEL immune complexes in the absence of T lymphocytes,
background proliferation of the CTLL.2 cells was observed
(data not shown). In addition, all the experiments were re-
peated with paraformaldehyde-fixed APCs, a treatment
that completely prevents cytokine secretion (Fig. 3 and data
not shown). Under these conditions, only the T cell hy-
brids can produce IL-2.
The coactivation experiments (Fig. 4) show that presen-
tation of the FcgRIII-restricted epitopes was not a conse-
quence of overall cell activation. The most convincing re-
sult from this point of view may be the one shown in Fig. 4
C. When immune complexes were internalized by FcgRIIb2-
expressing cells in the continuous presence of F(ab)92 frag-
ments of anti-IgG antibodies, which efficiently induced cell
activation through mIgG (18), no presentation of the FcgRIII-
restricted epitopes was observed. It could be argued here
that cell activation through sIgG might be qualitatively dif-
ferent from cell activation through FcgRIII. Although we
can not completely exclude this possibility, we found that
direct antigen internalization though sIg (using A20 B cells
expressing anti-DNP sIg and DNP-derivatized CI l re-
pressor) allowed presentation of the same epitopes as Fc-
gRIII (data not shown). This shows that although presen-
tation of FcgRIII-restricted epitopes also occurred after
antigen internalization by sIg, overall cell activation through
sIg did not induce the presentation of those epitopes when
the antigen was internalized through FcgRIIb2. Therefore,
antigen must be physically associated to the receptor for the
efficient presentation of the FcgRIII-restricted epitopes. 
The simplest and most direct explanation for these results
is that FcgRIII targeted antigens to a particular intracellular
compartment that FcgRIIb2 can not access. Several of our
experiments support this possibility and, taken together,
shed light on various aspects of this putative transport path.
First, the differential generation of T cell epitopes after in-
ternalization by FcgRIIb2 and III was not due to selective
antigen targeting to the conventional and recycling presen-
tation pathways, since presentation of both dominant and
cryptic epitopes had slow kinetics and were blocked by cy-
cloheximide. This was an important possibility to test be-
cause it has recently been shown that the epitopes presented
by both pathways may be different (9).
Second, a single point mutation (of leucine 35 to alanine)
blocked the presentation of FcgRIII-restricted epitopes, with-
out affecting the presentation of the epitopes efficiently
presented after FcgRIIb2 internalization. In other words,
the chimeric FcgRII–icgL35A behaved exactly like FcgRIIb2
in terms of epitope presentation. Interestingly, L35A mutation
was first identified as blocking cell activation, but not receptor
internalization. Therefore, like FcgRIIb2, L35A chimeric
receptors are not capable of inducing activation of cytosolic
PTKs. These results suggest that association to tyrosine ki-
nases or tyrosine phosphorylation of the receptor itself is re-
quired for the efficient generation of the FcgRIII-restricted
epitopes.
In the case of PTK receptors, like the epidermal growth
factor receptor, the kinase activity has been shown to di-
rectly affect intracellular transport, since in addition to in-
ternalization (29) transport from endosomes to lysosomes
requires the kinase activity (30). Although the FcgRIII-
associated g chain contains no intrinsic PTK activity, it has
been shown to associate to Syk after phosphorylation of its
ITAM by PTK of the src family (17). In addition, for
ITAM-containing receptors like FcgRIII, association to
Syk is required for transport from endosomes to lysosomes
(Amigorena, S., and C. Bonnerot, unpublished results).
However,  transport to lysosomes is unlikely to be determi-
nant for presentation of the FcgRIII-restricted epitopes,
since FcgRIIb2 efficiently mediated transport of immune
complexes to Percoll heavy, degradative compartments (31).
Several recent studies have analyzed the intracellular lo-
cations where peptide loading occurs and showed that mul-
tiple endocytic compartments may be involved (32–34).
However, little is known about the actual influence of the
intracellular compartments where peptide loading occurs
on the generation of particular T cell epitopes (34). Indeed,
besides the affinity of peptides for MHC class II molecules,
other factors are critical for the formation of T cell epitopes.
The proteolytic generation of peptides, or their degradation
depends on specific proteolytic enzymes. The loading of
different peptides is differentially affected by HLA-DM
(35). Therefore, the endosomal environment most likely
determines the nature of the peptides loaded onto MHC
class II molecules (34).
We have previously shown that a particular population
of vesicles in the cells used here, class II vesicles or CIIV,
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fore, it is possible that FcgRIIb2 and FcgRIII (or FcgRII–
icg) have differential accessibilities to CIIV, thus account-
ing for the generation of different peptides after internaliza-
tion by these two receptors. Directly testing this possibility
will require an extensive analysis of FcgRIIb2 and FcgRIII
intracellular transport, which will next be undertaken. 
Physiologically, FcgRII and FcgRIII are expressed on
professional APCs such as macrophages and dendritic cells
(20, 38). Furthermore, the relative rates of expression of
these two receptors is regulated by cytokines such as IFN-g
and TNF-a (20). Our results therefore suggest that the se-
lection of peptides presented to T cells depends on the an-
tigen receptors expressed by the APCs which are them-
selves dependent on their microenvironment. 
The consequences of antigen receptor expression on the
presentation of different epitopes may also be relevant to
autoimmunity. Indeed, it has recently been proposed that
only dominant epitopes from autoantigens participate in
thymic selection, since cryptic epitopes would not be pre-
sented under normal conditions (3, 39). T cells specific for
cryptic epitopes from autoantigens therefore are not toler-
ized and may become pathogenic if cryptic epitopes are
presented in the periphery for any particular reason. In the
recent past, several groups have shown various mechanisms
for unveiling cryptic epitopes in vitro (for review see refer-
ence 39). Interestingly, after downregulation of a mem-
brane receptor antigen by its ligand, cryptic epitopes may
be revealed (40). Changes in the hierarchy of epitope pre-
sentation may also occur in different APCs or when anti-
gen is complexed to other proteins (such as antibodies)
(15). Our results indicate a novel mechanism of cryptic
epitope unveiling, i.e., receptor-mediated antigen uptake.
The participation of FcgRIII in revealing cryptic epitopes
in vivo, as well as the possible involvement of FcRs in
epitope spreading and in autoimmunity, have now to be
evaluated.
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